Amber Cai is a Venture Partner with F-Prime Capital, focusing on early-stage biotechnology investments. She is the founding CEO of Geneception, a leading gene and cell therapy company.

Prior to joining Geneception, Amber was a founding member of Novartis’ R&D Center in China, where she was most recently the Head of Operations and led the Center’s overall business operations overseeing a broad set of functions. During 2005-2006, Amber led the efforts to establish Novartis’ R&D presence in China from the concept stage to implementation. After the Center was established in 2006 as the first fully integrated research and development center in China by multinational pharma companies, she played an instrumental role in recruiting talent, establishing operations, developing Novartis’ China R&D strategy, and building strategic partnerships with government and other external stakeholders and collaborators. Prior to her work in China, Amber was with the Business Development at Novartis Institutes for BioMedical Researches in Cambridge, MA.

Amber has decades of experience in science before shifting her career into business. She completed her Ph.D. at Massachusetts Institute of Technology in GPCR signaling and holds an MBA degree from MIT Sloan School of Management.